RAPT Therapeutics, Inc.
RAPT
$0.906
-$0.0151-1.64%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 24.11% | -6.51% | -0.48% | 29.21% | 29.66% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 63.97% | -41.66% | 3.41% | 3.03% | 35.96% |
| Operating Income | -63.97% | 41.66% | -3.41% | -3.03% | -35.96% |
| Income Before Tax | -72.46% | 41.25% | -9.43% | -4.27% | -34.53% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -72.46% | 41.25% | -9.43% | -4.27% | -34.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -72.46% | 41.25% | -9.43% | -4.27% | -34.53% |
| EBIT | -63.97% | 41.66% | -3.41% | -3.03% | -35.96% |
| EBITDA | -64.70% | 41.98% | -3.31% | -3.01% | -36.04% |
| EPS Basic | -41.78% | 42.06% | -7.90% | -3.35% | -25.08% |
| Normalized Basic EPS | -37.73% | 42.08% | -7.91% | -1.68% | -26.44% |
| EPS Diluted | -41.78% | 42.06% | -7.90% | -3.35% | -25.08% |
| Normalized Diluted EPS | -37.73% | 42.08% | -7.91% | -1.68% | -26.44% |
| Average Basic Shares Outstanding | 21.63% | 1.42% | 1.40% | 0.90% | 7.55% |
| Average Diluted Shares Outstanding | 21.63% | 1.42% | 1.40% | 0.90% | 7.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |